Literature DB >> 8995602

Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques.

L Giavedoni1, S Ahmad, L Jones, T Yilma.   

Abstract

Simian immunodeficiency virus (SIV) infection of macaques is a model for human immunodeficiency virus (HIV) infection. We have previously reported the construction and characterization of an SIV vector with a deletion in the nef gene (SIV(delta nef)) and expressing gamma interferon (SIV(HyIFN)) (L. Giavedoni and T. Yilma, J. Virol. 70:2247-2251, 1996). We now show that rhesus macaques vaccinated with SIV(HyIFN) have a lower viral load than a group similarly immunized with SIV(delta nef). Viral loads remained low in the SIV(HyIFN)-vaccinated group even though SIV expressing gamma interferon could not be isolated after 6 weeks postimmunization in these animals. All immunized and two naive control macaques became infected when challenged with virulent SIV(mac251), at 25 weeks postvaccination. In contrast to the two naive controls that died by 12 and 18 weeks postchallenge, all vaccinated animals remained healthy for more than 32 weeks. In addition, postchallenge cell-associated virus load was significantly lower in SIV(HyIFN)-immunized animals than in the group vaccinated with SIV(delta nef). These findings indicate that cytokine-expressing viruses can provide a novel approach for development of safe and efficacious live attenuated vaccines for AIDS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995602      PMCID: PMC191133     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Recombinant human interferons inhibit replication of Mason-Pfizer monkey virus in primate cells.

Authors:  S Chatterjee; E Hunter
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

2.  AIDS vaccine research. A new goal: preventing disease, not infection.

Authors:  J Cohen
Journal:  Science       Date:  1993-12-17       Impact factor: 47.728

3.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Inhibition of Rev-mediated HIV-1 expression by an RNA binding protein encoded by the interferon-inducible 9-27 gene.

Authors:  P Constantoulakis; M Campbell; B K Felber; G Nasioulas; E Afonina; G N Pavlakis
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

5.  Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.

Authors:  S Ahmad; B Lohman; M Marthas; L Giavedoni; Z el-Amad; N L Haigwood; C J Scandella; M B Gardner; P A Luciw; T Yilma
Journal:  AIDS Res Hum Retroviruses       Date:  1994-02       Impact factor: 2.205

6.  Titration and characterization of two rhesus-derived SIVmac challenge stocks.

Authors:  M G Lewis; S Bellah; K McKinnon; J Yalley-Ogunro; P M Zack; W R Elkins; R C Desrosiers; G A Eddy
Journal:  AIDS Res Hum Retroviruses       Date:  1994-02       Impact factor: 2.205

7.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

8.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Authors:  K K Van Rompay; M L Marthas; R A Ramos; C P Mandell; E K McGowan; S M Joye; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.

Authors:  D Chargelegue; B T Colvin; C M O'Toole
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

View more
  20 in total

1.  A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.

Authors:  Theresa Li-Yun Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus.

Authors:  L D Giavedoni; M C Velasquillo; L M Parodi; G B Hubbard; V L Hodara
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  Expression of CD154 by a simian immunodeficiency virus vector induces only transitory changes in rhesus macaques.

Authors:  Vida L Hodara; M Cristina Velasquillo; Laura M Parodi; Luis D Giavedoni
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines.

Authors:  B R Gundlach; S Reiprich; S Sopper; R E Means; U Dittmer; K Mätz-Rensing; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Tilahun D Yilma
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Authors:  M G Lewis; J Yalley-Ogunro; J J Greenhouse; T P Brennan; J B Jiang; T C VanCott; Y Lu; G A Eddy; D L Birx
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Transfected Plasmodium knowlesi produces bioactive host gamma interferon: a new perspective for modulating immune responses to malaria parasites.

Authors:  Hastings Ozwara; Jan A M Langermans; Clemens H M Kocken; Annemarie van der Wel; Peter H van der Meide; Richard A W Vervenne; Jason M Mwenda; Alan W Thomas
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.